Hormonal Therapy News and Research

RSS

Hormonal Therapy is treatment that adds, blocks, or removes hormones. For certain conditions (such as diabetes or menopause), hormones are given to adjust low hormone levels. To slow or stop the growth of certain cancers (such as prostate and breast cancer), synthetic hormones or other drugs may be given to block the body’s natural hormones. Sometimes surgery is needed to remove the gland that makes a certain hormone. Also called endocrine therapy, hormone therapy, and hormone treatment.

Non-BRCA1/2 hereditary breast cancer linked to new cancers

The risk for a new cancer in the unaffected breast substantially increases in women diagnosed with unilateral, hereditary (non-BRCA1/2) breast cancer, according to a new study by researchers working at Karolinska Institutet in Stockholm, Sweden.

14 Feb 2006

Early prediction of endocrine therapy effect in advanced breast cancer patients using nuclear medicine imaging

Innovative use of somatostatin receptor scintigraphy (SRS), a nuclear medicine imaging technique looking at how the body functions at the molecular level, may provide near immediate selection of breast cancer patients for endocrine therapy and offers a new tool in fighting the disease

23 Jan 2006

New therapies for prostate cancer

A Dutch study suggested treating prostate cancer patients with higher doses of radiotherapy significantly improved patient outcome and treatment over a five-year period.

3 Nov 2005

DN-101 may protect against major side effects of chemotherapy

Men with advanced prostate cancer who take an experimental, high-dose vitamin D pill with chemotherapy live about eight months longer than those receiving chemotherapy and placebo, according to a new study.

3 Nov 2005

Early diagnosis guarantees therapeutic success in breast cancer

Breast cancer is the most common tumour amongst the female population. In recent years its prevalence has increased considerably without the reasons thereof being very clear, although lifestyle changes such as first pregnancy taking place at a later age or the reduction in the period of breast-feeding may play an important role.

25 Oct 2005

Americans' risk of dying from cancer continues to decline

The nation's leading cancer organizations report that Americans' risk of dying from cancer continues to decline and that the rate of new cancers is holding steady. The "Annual Report to the Nation on the Status of Cancer, 1975-2002," published in the Oct. 5, 2005, issue of the Journal of the National Cancer Institute, shows observed cancer death rates from all cancers combined dropped 1.1 percent per year from 1993 to 2002.

4 Oct 2005

PSA screening of asymptomatic men reduced risk of metastatic prostate cancer by 35 per cent

Early screening of prostate cancer in asymptomatic men may reduce their risk of death from metastatic prostate cancer by as much as 35 per cent, researchers from the University of Toronto have found.

11 Jul 2005

Some men with breast cancer may be having unnecessary radiotherapy

A study carried out at the British Columbia Cancer Agency in Vancouver, British Columbia, Canada, showed that men whose cancer had not spread beyond the breast were almost six times more likely to be given radiotherapy than were women with the equivalent stage of disease.

21 Jun 2005

Vitamin D, taxotere combination promising for advanced prostate cancer

Results of a new study strongly suggest that DN-101, a new high-dose calcitriol pill designed specifically as a cancer therapy, given in combination with docetaxel (Taxotere) extends the lives of men with advanced prostate cancer.

17 May 2005

Zometa reduces bone loss in patients receiving breast cancer treatment

Data presented at the American Society of Clinical Oncology (ASCO) annual meeting in Orlando, Florida, demonstrate that Zometa (zoledronic acid), an intravenous bisphosphonate, was shown to inhibit bone loss in postmenopausal women treated with Femara (letrozole) in the adjuvant breast cancer setting (directly following surgery to prevent cancer recurrence).

16 May 2005

Great news for breast cancer patients

In encouraging new study results researchers say that modern treatments have significantly boosted the 15-year survival rate for breast cancer, and even better news is that they have also found that drug and hormonal therapies effectively cure many women, rather than simply delaying the recurrence of disease.

12 May 2005

Breast cancer gene may play a major role in the recurrence of prostate cancer

A gene associated with breast cancer also may play a major role in the recurrence of prostate cancer, according to new research from the University of North Carolina at Chapel Hill School of Medicine and UNC Lineberger Comprehensive Cancer Center.

20 Apr 2005

Herceptin - more powerful treatment for patients with HER-2-positive breast cancer

A new use of the drug Herceptin appears to offer a much more powerful treatment advantage than expected for patients with HER-2-positive breast cancer, say researchers at The University of Texas M. D. Anderson Cancer Center.

29 Mar 2005

Timing is everything when it comes to killing prostate cancer cells

"The window of opportunity is narrow for vaccination, designed to reinvigorate the immune system's attack on cancer cells, and it occurs right after hormonal therapy begins to wipe out the tumor and immune cells outnumber cancerous ones," according to Charles Drake, M.D., Ph.D.

15 Mar 2005

Over-the-counter DHEA hormonal therapy may be an effective treatment for depression

The over-the-counter hormonal therapy known as DHEA may be an effective treatment of midlife-onset minor and major depression, according to a study in the February issue of The Archives of General Psychiatry. DHEA (dehydroepiandrosterone), an adrenal androgen and neurosteroid is available as a supplement in the U.S.

7 Feb 2005

$Phenoxodiol gets fast track status for its intended use in patients with hormone-refractory prostate cancer$

Phenoxodiol gets fast track status for its intended use in patients with hormone-refractory prostate cancer

Marshall Edwards today announced that the U.S. Food and Drug Administration (FDA) has granted the investigational anti-cancer drug, phenoxodiol, fast track status for its intended use in patients with hormone- refractory prostate cancer (HRPC).

26 Jan 2005

New approach to genomic testing identifies women with low risk of breast cancer recurrence

An initial validation study presented by Exagen Diagnostics at the San Antonio Breast Cancer Symposium suggests it may soon be possible to distinguish good prognosis from poor prognosis in any newly diagnosed breast cancer patient based on DNA changes in the patient's tumor.

13 Dec 2004

Guidelines needed for the use of androgens for women with sexual dysfunction

The Endocrine Society, which represents more than 12,000 endocrinologists who are specially trained to diagnose, treat and conduct basic and clinical research on complex hormonal disorders, has called for new clinical guidelines on the use of androgens in women/female sexual dysfunction.

3 Dec 2004

36% of cancer patients ages 65 and older participate in clinical trials

A new study finds that only 36% of cancer patients ages 65 and older participate in clinical trials, despite making up 60% of the U.S. cancer population. The study will be published November 15 in the Journal of Clinical Oncology (JCO).

14 Nov 2004

European approval for Taxotere (docetaxel) in prostate cancer

Aventis, part of the sanofi-aventis Group announced today that the European Commission has approved Taxotere (docetaxel) Injection Concentrate for use in combination with prednisone as a treatment for men with androgen-independent (hormone- refractory) metastatic prostate cancer.

4 Nov 2004